Why Global Blood Therapeutics Is Rallying Today

·2-min read
Why Global Blood Therapeutics Is Rallying Today

Sales of its sickle cell disease drug Oxbryta shot up 51% year over year to $47.6 million. SCD is a severe hereditary disease that causes distortions in blood hemoglobin. The irregularly shaped red blood cells can then block blood vessels, causing a life-threatening condition called a vaso-occlusive crisis.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting